Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of WEE1 inhibition on the replication timing program

ABSTRACT: As a part of the project looking into the role of WEE1 in regulating replication initiation, we report the replication timing analysis of the U2OS cells treated with WEE1 kinase inhibitor AZD1775

ORGANISM(S): Homo sapiens

PROVIDER: GSE138998 | GEO | 2019/12/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

The effect of ATR inhibition on the replication timing program

Project description:As a part of the project looking into the role of ATR in regulating replication initiation, we report the replication timing analysis of the U2OS cells treated with ATR kinase inhibitor AZD6738

2019-07-26 | GSE131018 | GEO

The effect of WEE1 inhibition on the replication timing program

Project description:The effect of WEE1 inhibition on the replication timing program

| PRJNA577964 | ENA

Replication timing program in 6 human model cell lines

Project description:We present here the characterization of the replication timing program in 6 human cell lines : U2OS, RKO, 293T, HeLa, MRC5 and K562

2016-07-08 | GSE80029 | GEO

The effect of ATR inhibition on the replication timing program

Project description:as a part of the project looking into the role of ATR in regulating replication initiation and to investigate the rapid replication of CD8+ T cells, we report the replication timing analysis of murine CD8+ T cells and fibroblasts treated with ATR kinase inhibitor AZD6738

2022-05-01 | GSE183412 | GEO

Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia

Project description:WEE1 is a cell cycle and DNA damage response kinase that is emerging as a therapeutic target for cancer. AZD1775 is a small molecule inhibitor of WEE1, currently in early phase clinical trials as a single agent and in combination with more conventional anti-neoplastic agents. As resistance to kinase inhibitors is frequent, we sought to identify mechanisms of resistance to WEE1 inhibition in acute leukemia. We found that AZD1775 resistant cell lines are dependent upon increased HDAC activity for their survival, in part due to increased KDM5A activity. In addition, gene expression analyses demonstrate HDAC dependent increase in MYC expression and c-MYC activity in AZD1775 treated resistant cells. Overexpression of c-MYC confers resistance to AZD1775 in cell lines with low base line expression. Pharmacologic inhibition of BRD4, and thereby c-MYC, partially abrogated resistance to AZD1775. Thus, acquired resistance to WEE1 inhibition may be reversed by HDAC or BRD4 inhibition in leukemia cells.

2020-02-25 | GSE145129 | GEO

Development and Characterization of a Wee1 Kinase Degrader

Project description:The G1/S cell-cycle checkpoint is frequently dysregulated in cancer, leaving cancer cells particularly reliant on a functional G2/M checkpoint to prevent excessive DNA damage. Inhibiting regulators of the G2/M checkpoint can therefore drive cancer cells into premature mitosis, ultimately causing cell death by mitotic catastrophe. One such regulator is Wee1, a nuclear tyrosine kinase that delays mitotic entry by phosphorylating CDK1 at Tyr15. Previous drug development efforts targeting Wee1 resulted in the clinical-grade inhibitor, AZD1775. However, AZD1775 is burdened by dose- limiting adverse events, and has off-target PLK1 activity. In an attempt to overcome these limitations, we designed small molecule degraders of Wee1 by conjugating AZD1775 to the cereblon (CRBN)- binding ligand, pomalidomide, as informed by molecular docking. The resulting lead compound, ZNL- 02-096, degrades Wee1 while sparing PLK1, induces G2/M phase accumulation at up to 10-fold lower concentrations than AZD1775, and potently synergizes with Olaparib in ovarian cancer cell lines. We demonstrate that ZNL-02-096 has CRBN-dependent pharmacology that is distinct from the conventional catalytic inhibitor, AZD1775, which justifies further evaluation of selective Wee1 degraders.

2019-11-18 | PXD015513 | Pride

Single-cell replication profiling reveals stochastic regulation of the mammalian replication-timing program [population]

Project description:This study demonstrates the stochastic nature of DNA replication-timing regulation by measures genome-wide replication timing in single-cells

2017-12-19 | GSE102076 | GEO

Single-cell replication profiling reveals stochastic regulation of the mammalian replication-timing program [WGA]

Project description:This study demonstrates the stochastic nature of DNA replication-timing regulation by measures genome-wide replication timing in single-cells

2017-12-19 | GSE102075 | GEO

Single-cell replication profiling reveals stochastic regulation of the mammalian replication-timing program [SEQXE]

Project description:This study demonstrates the stochastic nature of DNA replication-timing regulation by measuring genome-wide replication timing in single-cells

2017-12-19 | GSE102074 | GEO

Identifying and overcoming a mechanism of resistance to Wee1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells (OVCAR8)

Project description:Treatment of Human high grade serous ovarian cancer cell line, OVCAR8, with WEE1 kinase inhibitor AZD1775

2020-12-01 | GSE141990 | GEO